Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Sabina Signoretti, M.D.

Co-Author

This page shows the publications co-authored by Sabina Signoretti and David McDermott.
Connection Strength

2.706
  1. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2022 Jul 08.
    View in: PubMed
    Score: 0.246
  2. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
    View in: PubMed
    Score: 0.220
  3. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.194
  4. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436.
    View in: PubMed
    Score: 0.178
  5. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
    View in: PubMed
    Score: 0.158
  6. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
    View in: PubMed
    Score: 0.150
  7. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8.
    View in: PubMed
    Score: 0.145
  8. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8.
    View in: PubMed
    Score: 0.105
  9. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15; 11(10):3714-21.
    View in: PubMed
    Score: 0.075
  10. Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. Eur Urol. 2022 Sep; 82(3):247-251.
    View in: PubMed
    Score: 0.061
  11. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 Sep 01; 40(25):2913-2923.
    View in: PubMed
    Score: 0.061
  12. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2022 03 01; 28(5):831-839.
    View in: PubMed
    Score: 0.060
  13. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190.
    View in: PubMed
    Score: 0.059
  14. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.056
  15. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.056
  16. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 02; 9(2):156-169.
    View in: PubMed
    Score: 0.055
  17. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.055
  18. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2021 01 01; 27(1):78-86.
    View in: PubMed
    Score: 0.054
  19. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.053
  20. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.051
  21. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 09 25; 10(1):4346.
    View in: PubMed
    Score: 0.051
  22. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.049
  23. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018 09; 14(9):e1007679.
    View in: PubMed
    Score: 0.047
  24. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):341-348.
    View in: PubMed
    Score: 0.046
  25. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Oct 20; 34(30):3655-3663.
    View in: PubMed
    Score: 0.041
  26. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017 May 01; 23(9):2159-2168.
    View in: PubMed
    Score: 0.041
  27. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 12; 65(12):1523-1532.
    View in: PubMed
    Score: 0.041
  28. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
    View in: PubMed
    Score: 0.041
  29. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
    View in: PubMed
    Score: 0.040
  30. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
    View in: PubMed
    Score: 0.040
  31. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6.
    View in: PubMed
    Score: 0.040
  32. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 01; 121(19):3435-43.
    View in: PubMed
    Score: 0.038
  33. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.032
  34. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51.
    View in: PubMed
    Score: 0.025
  35. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007 Sep; 5(6):379-85.
    View in: PubMed
    Score: 0.022
  36. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005 Apr 15; 65(8):3044-8.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.